BIIB080治疗阿尔茨海默病的多剂量递增研究:探索性tau生物标志物结果:一项随机临床试验
这项随机、双盲、安慰剂对照的1b期多剂量递增试验在加拿大和欧洲12个中心纳入46例轻度阿尔茨海默病且淀粉样蛋白病理确认的患者,评估鞘内注射MAPT靶向反义寡核苷酸BIIB080的安全性及对tau生物标志物的影响。BIIB080总体耐受良好,与脑脊液t-tau和p-tau181的剂量依赖性降低相关,tau PET显示较安慰剂积累减少,100周时各区域较基线降低。
要点
- BIIB080在轻度阿尔茨海默病患者中总体耐受良好。
- BIIB080与脑脊液t-tau和p-tau181剂量依赖性降低相关。
- tau PET显示BIIB080较安慰剂减少积累,100周时各区域较基线降低。
核心结论
- BIIB080降低了轻度阿尔茨海默病参与者的tau生物标志物,包括脑脊液t-tau、脑脊液p-tau181和tau PET。
- BIIB080对生物标志物和临床结局的影响正在一项2期试验中进一步评估。
研究设计与样本
- 随机、双盲、安慰剂对照36周多剂量递增(MAD)1b期试验(2017年10月至2020年9月),随后64周或71周开放标签长期扩展(LTE)(2019年10月至2022年5月)。
- 在加拿大和欧洲12个中心评估资格后,轻度阿尔茨海默病且淀粉样蛋白病理确认的参与者按3:1(BIIB080:安慰剂)随机分入4个剂量队列。
- MAD期活动剂量组包括10 mg每4周、30 mg每4周、60 mg每4周和115 mg每12周;LTE期包括60 mg每12周或115 mg每12周。
- 共评估102例参与者,纳入46例轻度阿尔茨海默病患者;23例(50%)为女性,平均(SD)年龄65.8(5.70)岁。
主要发现
- BIIB080总体耐受良好,MAD期与脑脊液t-tau和p-tau181的剂量依赖性降低相关(2个较高剂量队列脑脊液t-tau降低56%,95%CI 50%至62%;p-tau181降低51%,95%CI 38%至63%),并在LTE季度给药期间持续和/或维持。
- tau PET显示第25周时BIIB080较安慰剂积累减少(n=13)。
- 第100周时tau PET显示所有评估区域较基线降低(n=12), temporal复合区域较基线降低幅度最大(-0.71 SUVR;95%CI -1.40至-0.02)。
- 模型预测的脑脊液药物累积暴露与tau PET变化之间观察到中等相关性。
关键数值与推荐
- MAD期2个较高剂量队列脑脊液t-tau降低56%(95%CI 50%至62%)。
- MAD期2个较高剂量队列脑脊液p-tau181降低51%(95%CI 38%至63%)。
- 第100周 temporal复合区域tau PET较基线变化-0.71 SUVR(95%CI -1.40至-0.02)(n=12)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Accumulation of hyperphosphorylated, tangled microtubule-associated protein tau (MAPT) is a pathological hallmark of Alzheimer disease (AD) associated with disease progression and cognitive decline. OBJECTIVE: To evaluate the effect of tau synthesis reduction on tau biomarkers in patients with mild AD. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a double-blind, placebo-controlled 36-week multiple-ascending dose (MAD) phase 1b trial (October 2017 to September 2020), followed by a 64- or 71-week open-label long-term extension (LTE) (October 2019 to May 2022). After being assessed for eligibility at 12 sites in Canada and Europe, participants with mild AD and confirmed amyloid pathology were randomized 3:1 (BIIB080:placebo) in 4 dose cohorts. INTERVENTION: Intrathecal administration of BIIB080, a MAPT-targeting antisense oligonucleotide, or placebo. Active dose arms included 10 mg every 4 weeks, 30 mg every 4 weeks, 60 mg every 4 weeks, and 115 mg every 12 weeks during the MAD period and 60 mg every 12 weeks or 115 mg every 12 weeks during the LTE. MAIN OUTCOME AND MEASURES: The original primary end point was safety. Additionally, BIIB080, total tau (t-tau), and phosphorylated tau 181 (p-tau181) cerebrospinal fluid (CSF) concentrations were evaluated. Tau positron emission tomography (PET) was collected in a substudy, and standard uptake value ratios (SUVRs) were calculated in a priori-defined composite regions of interest. RESULTS: Of 102 participants assessed for eligibility, 46 participants with mild AD were enrolled; 23 (50%) were female, and mean (SD) age was 65.8 (5.70) years. BIIB080 was generally well tolerated and was associated with a dose-dependent reduction in CSF t-tau and p-tau181 in the MAD period (56% reduction; 95% CI, 50% to 62%; and 51% reduction; 95% CI, 38% to 63%, of CSF t-tau in the 2 higher-dose cohorts) that continued and/or was maintained through quarterly dosing in the LTE. Tau PET demonstrated reduced accumulation vs placebo at week 25 (n = 13). At week 100, tau PET showed a reduction from baseline across all regions assessed (n = 12), with the largest reductions from baseline observed in the temporal composite (-0.71 SUVR; 95% CI, -1.40 to -0.02). A moderate correlation was observed between model-predicted cumulative CSF drug exposure and tau PET change. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, BIIB080 reduced tau biomarkers, including CSF t-tau, CSF p-tau181, and tau PET, which is associated with cognitive decline, in participants with mild AD. Effects of BIIB080 on biomarkers and clinical outcomes are being further evaluated in a phase 2 trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03186989.
引用
- Edwards AL, Collins JA, Junge C, et al. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37902726. doi:10.1001/jamaneurol.2023.3861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。